A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

NCT06213844 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants
Asthma

Interventions

DRUG: IBI3002
DRUG: Placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.